Xolair

(Omalizumab)

Xolair

Drug updated on 9/13/2023

Dosage FormInjection (subcutaneous; 75 mg/0.5mL, 150 mg/mL)
Drug ClassAnti-IgE antibody
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For moderate to severe persistent asthma in adults and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids.
  • For chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids, as add-on maintenance treatment.
  • For chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment.

Product Monograph / Prescribing Information

Document TitleYearSource
Xolair (omalizumab) Prescribing Information.2023Genentech Inc., South San Francisco, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines